Agenus Inc. (AGEN) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Jeannie and I will be your conference operator today. At this time, I would like to welcome everyone to the AGENAS Q3 2023 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star 1. Thank you. Zach Arman, you may begin your conference. Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory, and commercial plans and timelines. as well as timelines for data release and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our ITC filings available on our website for more details on these risks. Joining me today are Dr. Garrow Harmon, Chairman and Chief Executive Officer, Dr. Stephen O'Day, Chief Medical Officer, Chief Commercial Officer, we will be participating in the Q&A session. Now, I'd like to turn the call over to Gero to highlight our progress and speak to our outlets for the remainder of the year. Gero. Thank you, Zach. Ladies and gentlemen, as we gather today for the earnings call, let's reflect on the remarkable patient outcomes from our Botanacillinab trial. As underscored by our leading experts and researchers, we're witnessing sustained benefits in treating some of the most challenging cancers. Based on these observations and for the sa...